Literature DB >> 23806554

3-Aryl-3-arylmethoxyazetidines. A new class of high affinity ligands for monoamine transporters.

Amber Thaxton1, Sari Izenwasser, Dean Wade, Edwin D Stevens, David L Mobley, Vivian Jaber, Stacey A Lomenzo, Mark L Trudell.   

Abstract

A series of 3-aryl-3-arylmethoxy-azetidines were synthesized and evaluated for binding affinities at dopamine and serotonin transporters. The 3-aryl-3-arylmethoxyazetidines were generally SERT selective with the dichloro substituted congener 7c (Ki=1.0 nM) and the tetrachloro substituted derivative 7i (Ki=1.3 nM) possessing low nanomolar affinity for the SERT. The 3-(3,4-dichlorophenyl-3-phenylmethoxyazetidine (7g) exhibited moderate affinity at both DAT and SERT transporters and suggests that substitution of the aryl rings can be used to tune the mononamine transporter affinity.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23806554      PMCID: PMC3733996          DOI: 10.1016/j.bmcl.2013.05.071

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

Review 1.  Serotonin reuptake inhibition: an update on current research strategies.

Authors:  D Spinks; G Spinks
Journal:  Curr Med Chem       Date:  2002-04       Impact factor: 4.530

2.  Neurochemical neutralization of methamphetamine with high-affinity nonselective inhibitors of biogenic amine transporters: a pharmacological strategy for treating stimulant abuse.

Authors:  R B Rothman; J S Partilla; M H Baumann; C M Dersch; F I Carroll; K C Rice
Journal:  Synapse       Date:  2000-03-01       Impact factor: 2.562

Review 3.  Reboxetine: the first selective noradrenaline re-uptake inhibitor.

Authors:  S Kasper; N el Giamal; E Hilger
Journal:  Expert Opin Pharmacother       Date:  2000-05       Impact factor: 3.889

4.  In vivo effects of amphetamine analogs reveal evidence for serotonergic inhibition of mesolimbic dopamine transmission in the rat.

Authors:  Michael H Baumann; Robert D Clark; William L Woolverton; Sunmee Wee; Bruce E Blough; Richard B Rothman
Journal:  J Pharmacol Exp Ther       Date:  2011-01-12       Impact factor: 4.030

Review 5.  Pharmacological approaches to methamphetamine dependence: a focused review.

Authors:  Laurent Karila; Aviv Weinstein; Henri-Jean Aubin; Amine Benyamina; Michel Reynaud; Steven L Batki
Journal:  Br J Clin Pharmacol       Date:  2010-06       Impact factor: 4.335

Review 6.  Reboxetine: additional benefits to the depressed patient.

Authors:  S A Montgomery
Journal:  J Psychopharmacol       Date:  1997       Impact factor: 4.153

7.  Synthesis and biological evaluation of meperidine analogues at monoamine transporters.

Authors:  Stacey A Lomenzo; Jill B Rhoden; Sari Izenwasser; Dean Wade; Theresa Kopajtic; Jonathan L Katz; Mark L Trudell
Journal:  J Med Chem       Date:  2005-03-10       Impact factor: 7.446

Review 8.  Dual dopamine/serotonin releasers: potential treatment agents for stimulant addiction.

Authors:  Richard B Rothman; Bruce E Blough; Michael H Baumann
Journal:  Exp Clin Psychopharmacol       Date:  2008-12       Impact factor: 3.157

9.  Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes.

Authors:  Harneet Kaur; Sari Izenwasser; Abha Verma; Dean Wade; Amy Housman; Edwin D Stevens; David L Mobley; Mark L Trudell
Journal:  Bioorg Med Chem Lett       Date:  2009-10-23       Impact factor: 2.823

10.  Synthesis and profiling of a diverse collection of azetidine-based scaffolds for the development of CNS-focused lead-like libraries.

Authors:  Jason T Lowe; Maurice D Lee; Lakshmi B Akella; Emeline Davoine; Etienne J Donckele; Landon Durak; Jeremy R Duvall; Baudouin Gerard; Edward B Holson; Adrien Joliton; Sarathy Kesavan; Berenice C Lemercier; Haibo Liu; Jean-Charles Marié; Carol A Mulrooney; Giovanni Muncipinto; Morgan Welzel-O'Shea; Laura M Panko; Ann Rowley; Byung-Chul Suh; Meryl Thomas; Florence F Wagner; Jingqiang Wei; Michael A Foley; Lisa A Marcaurelle
Journal:  J Org Chem       Date:  2012-08-10       Impact factor: 4.354

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.